menu search

syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)

syfovre reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sha...

November 4, 2023, 5:37 pm

Apellis (apls) q3 loss wider than expected, syfovre drives sales

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, ...

November 2, 2023, 12:47 pm

Apellis pharmaceuticals reports third quarter 2023 financial results

Generated total revenues of $110.4 million in the third quarter, including $75.3 million for syfovre® ...

November 1, 2023, 11:05 am

Apellis announces preliminary u.s. net revenues of approximately $74 million for syfovre® (pegcetacoplan injection) in the third quarter of 2023

Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting i...

October 5, 2023, 11:00 am

Lifshitz law pllc announces investigations of apellis pharmaceutics, inc. (nasdaq: apls), rtx corp. (nyse: rtx), live nation entertainment, inc. (nyse: lyv), and keycorp (nyse: key)

NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Lifshitz Law PLLC announces investigation into possible sec...

September 2, 2023, 11:00 pm

Apellis (apls) dips on layoffs amid syfovre safety issues

Apellis (APLS) plans to initiate restructuring plans to strengthen its commercial portfolio and curb cash burn....

August 30, 2023, 9:46 am

Biopharmaceutical stock soars on positive drug update

The shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) are soaring, after the biopharmaceutical concern identified the potential cause of an issue w...

August 23, 2023, 11:22 am

Why is apellis pharmaceuticals (apls) stock up 23% today?

Apellis Pharmaceuticals (NASDAQ: APLS ) stock is on the rise Wednesday after the biopharmaceutical company announced an update on injection kits. The...

August 23, 2023, 8:28 am

Apellis pharmaceuticals stock jumps on safety review update

Apellis Pharmaceuticals Inc (NASDAQ:APLS) jumped some 30% in Wednesday's premarket after last night updating investors on an ongoing safety review of ...

August 23, 2023, 7:52 am

Apellis (apls) focuses on empaveli to fuel its growth

Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, ...

August 15, 2023, 10:55 am

Apellis (apls) q2 earnings top, syfovre sales boost revenues

Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding ...

August 1, 2023, 11:55 am

syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 30 months in patients with geographic atrophy (ga)

syfovre reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected s...

July 30, 2023, 5:00 pm

Apellis provides update on review of rare safety events with syfovre® (pegcetacoplan injection) for geographic atrophy

No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis Confirmed seven total events of non-occlusive...

July 29, 2023, 6:52 pm

First-to-market edge for apellis’s syfovre in geographic atrophy diminished in the face of an unexpected safety signal

Prospects for syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflam...

July 28, 2023, 4:26 pm

Apellis (apls) plunges on safety issues with eye treatment

Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with ...

July 19, 2023, 12:52 pm

Apellis: exercise caution in response to safety signal (rating downgrade)

Apellis Pharmaceuticals, Inc. shares dropped 37% following reports of eye inflammation cases related to its geographic atrophy treatment, ...

July 18, 2023, 10:08 am

Apellis (apls) q1 earnings miss, empaveli & syfovre fuel growth

Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and syfovre...

May 5, 2023, 10:40 am

Top-notch biotech apellis soars after new drug obliterates sales views

Apellis' new eye drug, syfovre, crushed expectations in its first quarter post launch, putting APLS sto...

May 5, 2023, 9:36 am

Apellis presents phase 3 functional analyses of syfovre™ (pegcetacoplan injection) for geographic atrophy

Showed visual function and quality-of-life benefits in patients with extrafoveal lesions Slowed the loss of retinal pigmented epithelial and photorece...

April 23, 2023, 10:05 pm

Apellis (apls) stock up 50% in three months: here's why?

Apellis (APLS) stock rises 50% in the past three months owing to the approval of syfovre (pegcetacoplan...

April 11, 2023, 12:16 pm


Search within

Pages Search Results: